Yes. As of September 2026, Vertex Pharmaceuticals Incorporated (VRTX) is classified as HALAL by Maz Vantage: it passes all 5 published Shariah screening standards it was tested against (AAOIFI, S&P Global, Dow Jones Islamic, MSCI and FTSE).
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 3.36% / 30% · (Cash+Inv) / Mkt Cap (36m) 7.37% / 30% · Interest income / Revenue 3.44% / 5% | Pass |
| S&P Global | Debt / Mkt Cap (36m) 3.36% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 4.71% / 33% · Receivables / Mkt Cap (36m) 1.73% / 49% · Interest income / Revenue 3.44% / 5% | Pass |
| Dow Jones Islamic | Debt / Mkt Cap (24m) 3.36% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 4.71% / 33.33% · Receivables / Mkt Cap (24m) 1.73% / 33.33% · Interest income / Revenue 3.44% / 5% | Pass |
| MSCI | Debt / Avg Assets (4Q) 4.00% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 24.9% / 33.33% · Receivables / Avg Assets (4Q) 7.56% / 33.33% · Interest income / Revenue 3.44% / 5% | Pass |
| FTSE | Debt / Total Assets 13.7% / 33.33% · (Cash+ST Inv) / Total Assets 19.3% / 33.33% · (Cash+Recv) / Total Assets 26.3% / 33.33% · Interest income / Revenue 3.44% / 5% | Pass |
Yes. As of September 2026, Vertex Pharmaceuticals Incorporated (VRTX) is classified as HALAL by Maz Vantage: it passes all 5 published Shariah screening standards it was tested against (AAOIFI, S&P Global, Dow Jones Islamic, MSCI and FTSE).
Yes. Vertex Pharmaceuticals Incorporated is within every AAOIFI limit: debt and interest-bearing cash and investments under 30% of its 36-month average market cap, and interest income under 5% of revenue.
About 3.44% of each dividend: Vertex Pharmaceuticals Incorporated's interest income as a share of its revenue. Give that share to charity; the dividend purification calculator works it out per holding.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) is a Healthcare company (Biotechnology) with a market capitalization of $136.4B. The Maz Rating grades it against the other companies in its sector.
Vertex Pharmaceuticals Incorporated's current Maz Rating and its five factor grades are for members: log in to see them.
At $537.79, Vertex Pharmaceuticals Incorporated trades at 34.3x trailing earnings, 10.5x sales and 6.5x book value, with an EV/EBITDA of 28.5. Over the last twelve months it generated about $13.0B of revenue and $4.0B of net income. It runs a gross margin of 85.5%, an operating margin of 33.2% and a net margin of 30.7%. It shows return on equity of 20.1%, return on invested capital of 12.5% and a free cash flow yield of 2.3%. On the balance sheet: a debt-to-equity ratio of 0.31 and a current ratio of 2.34. Over the past 52 weeks the share price ranged from $412.27 to $568.67, with a beta of 0.32.
Vertex Pharmaceuticals Incorporated does not currently pay a dividend.
56 Wall Street analyst ratings cover the stock: 49 Buy, 6 Hold and 1 Sell, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Vertex Pharmaceuticals Incorporated is a leading biotechnology firm primarily focused on the discovery, advancement, and marketing of innovative treatments, particularly for cystic fibrosis (CF). The company offers a range of approved medications for CF patients, including SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO, which target specific mutations within the cystic fibrosis transmembrane conductance regulator gene. Additionally, they provide TRIKAFTA for individuals with CF aged six years and older who possess at least one F508del mutation. Beyond its established CF therapies, Vertex maintains a robust and diverse clinical pipeline. This includes VX-864, currently in Phase 2 for alpha-1 antitrypsin (AAT) deficiency; VX-147, also in Phase 2, addressing APOL1-mediated focal segmental glomerulosclerosis (FSGS) and other serious kidney conditions; VX-880, a potential treatment for Type 1 Diabetes undergoing Phase 1/2 trials; VX-548, a NaV1.8 inhibitor in Phase 2 for various forms of acute, neuropathic, and musculoskeletal pain; and CTX001, which is in Phase 3 development for severe sickle cell disease (SCD) and transfusion-dependent beta-thalassemia (TDT). The company distributes its pharmaceutical products through specialty pharmacies and distributors across the United States, while international sales are facilitated via a network of specialty distributors, retail chains, hospitals, and clinics. Vertex also engages in numerous strategic collaborations with partners such as Affinia Therapeutics, Arbor Biotechnologies, CRISPR Therapeutics, Kymera Therapeutics, Mammoth Biosciences, Moderna, Obsidian Therapeutics, Skyhawk Therapeutics, Ribometrix, Genomics plc, Merck KGaA, and X-Chem. Established in 1989, Vertex Pharmaceuticals is headquartered in Boston, Massachusetts.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.